Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | APAF1 | O14727 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4552738 | 0.84 | MEN1 (0.40) | ALDH1A1HTTCASP3TSHRKMT2A | |
| SCHEMBL3243123 | 0.75 | ALDH1A1 (0.58) | ALDH1A1HTTHPGDHSD17B10MAPT | |
| SCHEMBL11667903 | 0.73 | KDM4E (0.40) | ALDH1A1HTTHPGDHSD17B10MAPT | |
| SCHEMBL11784496 | 0.72 | BCHE (0.43) | ALDH1A1ALOX15KMT2ACYP1A2CYP3A4 | |
| SCHEMBL45551 | 0.70 | FDPS (0.33) | CYP1A2CYP3A4CYP2D6CYP2C9KCNA5 | |
| SCHEMBL11122530 | 0.69 | POLB (0.51) | HPGDMAPTPKMKMT2ACYP1A2 | |
| SCHEMBL4623781 | 0.68 | TDP1 (0.49) | ALDH1A1HTTMAPTCASP3TSHR | |
| SCHEMBL11964484 | 0.68 | TDP1 (0.49) | ALDH1A1HTTMAPTCASP3TSHR | |
| SCHEMBL461207 | 0.68 | CASP3 (0.44) | ALDH1A1HTTHPGDHSD17B10MAPT | |
| SCHEMBL3259474 | 0.68 | CASP3 (0.44) | ALDH1A1HTTHPGDHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3113768-B1 | USE OF ARYLALKANOLAMINES AS SIGMA-1 RECEPTOR ANTAGONISTS | UNIV DEGLI STUDI DI PAVIA (IT) | 2018-09-26 | — | — | EP | disclosed |
| US-20170015640-A1 | USE OF ARYLALKANOLAMINES AS SIGMA-1 RECEPTOR ANTAGONISTS | UNIVERSITÀ DEGLI STUDI DI PAVIA (IT) | 2017-01-19 | — | — | US | disclosed |
| EP-3113768-A1 | USE OF ARYLALKANOLAMINES AS SIGMA-1 RECEPTOR ANTAGONISTS | Universita' Degli Studi Di Pavia (IT) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015132733-A1 | USE OF ARYLALKANOLAMINES AS SIGMA-1 RECEPTOR ANTAGONISTS | UNIVERSITA' DEGLI STUDI DI PAVIA (IT) | 2015-09-11 | — | — | WO | disclosed |
| EP-1590326-A4 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | LUNDBECK & CO AS H (DK) | 2008-04-30 | — | — | EP | disclosed |
| EP-1260512-B1 | NOVEL CYCLIC AMIDE DERIVATIVES | MITSUBISHI PHARMA CORP (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-7199135-B2 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2007-04-03 | — | — | US | disclosed |
| US-20060217418-A1 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2006-09-28 | — | — | US | disclosed |
| US-20060084649-A9 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2006-04-20 | — | — | US | disclosed |
| EP-1590326-A2 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. Lundbeck A/S (DK) | 2005-11-02 | — | — | EP | disclosed |
| US-5162341-A | Piperidine Derivatives | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-11-10 | — | — | US | disclosed |
| WO-1992018127-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0497843-A4 | (N-PHTHALIMIDOALKYL) PIPERIDINES | — | 1992-09-23 | — | — | EP | disclosed |
| EP-0497843-A4 | (N-PHTHALIMIDOALKYL) PIPERIDINES | — | 1992-09-23 | — | — | EP | disclosed |
| WO-1992014463-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS FOR TREATMENT OF AMPHETAMINE ABUSE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-09-03 | — | — | WO | disclosed |
| WO-1992014464-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS FOR TREATMENT OF COCAINE ABUSE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-09-03 | — | — | WO | disclosed |
| EP-0497843-A1 | (N-PHTHALIMIDOALKYL) PIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-08-12 | — | — | EP | disclosed |
| EP-0497843-A1 | (N-PHTHALIMIDOALKYL) PIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-08-12 | — | — | EP | disclosed |
| WO-1991006297-A1 | (N-PHTHALIMIDOALKYL) PIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-05-16 | — | — | WO | disclosed |
| WO-1991006297-A1 | (N-PHTHALIMIDOALKYL) PIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084649-A9 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | ALDH1A1 604/4885HTT 274/4885HPGD 2533/4885 |
| US-20170015640-A1 | USE OF ARYLALKANOLAMINES AS SIGMA-1 RECEPTOR ANTAGONISTS | SIGMAR1, OPRL1, OPRK1 | ALDH1A1 455/4885HTT 605/4885HPGD 3676/4885 |
| US-20060217418-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | ALDH1A1 604/4885HTT 274/4885HPGD 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.